Confo Therapeutics enters into drug discovery collaboration with Roche

Ghent, Belgium: 19 December 2017 - Confo Therapeutics, an emerging drug discovery company, announced today that it has entered into a research collaboration and license agreement with Roche for the discovery, development and commercialisation of novel, small molecule agonists of an undisclosed G-protein coupled receptor (GPCR) for the treatment of neurological and developmental disorders.

Under the terms of the agreement, Roche gains exclusive rights to the compounds resulting from the collaboration and will be responsible for their development, manufacturing and commercialisation. The financial terms include an upfront payment, pre-clinical milestones and research funding to Confo Therapeutics totalling € 6 million over the initial 30 months period of the collaboration. In addition, Confo Therapeutics is eligible to receive up to € 81.5 million of payments for certain development, regulatory and commercial milestones, plus tiered royalties on the annual net sales of any products resulting from the collaboration.

More info on Confo Therapeutics' website.


Next > Agendia and Bluebee Partner to Bring New NGS-Based MammaPrint®BluePrint® Breast Cancer Kit to Market

Previous > Mainstay Medical announces positive outcome of interim analysis